| Extecan vs King | 22–29 | 43.14% |
| Extecan vs Lili | 15–22 | 40.54% |
| Extecan vs Hwoarang | 12–23 | 34.29% |
| Extecan vs Fahkumram | 12–19 | 38.71% |
| Extecan vs Reina | 13–16 | 44.83% |
| Extecan vs Steve | 9–18 | 33.33% |
| Extecan vs Jin | 10–15 | 40.00% |
| Extecan vs Azucena | 6–19 | 24.00% |
| Extecan vs Kazuya | 7–17 | 29.17% |
| Extecan vs Dragunov | 10–13 | 43.48% |
| Extecan vs Law | 9–12 | 42.86% |
| Extecan vs Yoshimitsu | 9–10 | 47.37% |
| Extecan vs Eddy | 4–15 | 21.05% |
| Extecan vs Jack-8 | 8–10 | 44.44% |
| Extecan vs Asuka | 6–11 | 35.29% |
| Extecan vs Jun | 6–11 | 35.29% |
| Extecan vs Victor | 8–9 | 47.06% |
| Extecan vs Bryan | 5–11 | 31.25% |
| Extecan vs Alisa | 3–12 | 20.00% |
| Extecan vs Paul | 2–12 | 14.29% |
| Extecan vs Raven | 4–9 | 30.77% |
| Extecan vs Nina | 3–9 | 25.00% |
| Extecan vs Lidia | 7–4 | 63.64% |
| Extecan vs Heihachi | 5–6 | 45.45% |
| Extecan vs Anna | 6–5 | 54.55% |
| Extecan vs Lars | 3–7 | 30.00% |
| Extecan vs Xiaoyu | 2–7 | 22.22% |
| Extecan vs Lee | 4–5 | 44.44% |
| Extecan vs Clive | 5–4 | 55.56% |
| Extecan vs Leo | 1–6 | 14.29% |
| Extecan vs Zafina | 1–6 | 14.29% |
| Extecan vs Leroy | 3–4 | 42.86% |
| Extecan vs Feng | 1–4 | 20.00% |
| Extecan vs Kuma | 2–3 | 40.00% |
| Extecan vs Panda | 2–3 | 40.00% |
| Extecan vs Devil Jin | 2–2 | 50.00% |
| Extecan vs Claudio | 0–4 | 0.00% |
Limitations
This data is often requested to give insight into which characters you have more trouble with than others, but it is not particularly helpful for that. The main issue is that it is heavily skewed by how strong the opponents you play are.
For example, this data suggests my worst matchup is clearly vs Reina, but that's just because most of those games are vs Yagami.
There is a way to account for this being worked on. The central idea is to assign each matchup a rating vs you which adjusts based on the result, much like the regular rating but also based on the rating of each player. With this, it would give a better summary of how well you perform vs each character.
In the meantime, this page is here to present the data as requested.